CELYAD SA/ADR (NASDAQ:CYAD) Stock Rating Reaffirmed by HC Wainwright
Posted by Rex Bailey on Nov 24th, 2019
Share
CELYAD SA/ADR logoCELYAD SA/ADR (NASDAQ:CYAD)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Friday, AnalystRatings.com reports. They presently have a $43.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 242.36% from the company’s current price.
CYAD has been the subject of a number of other reports. William Blair restated an “outperform” rating on shares of CELYAD SA/ADR in a report on Monday, November 11th. ValuEngine upgraded CELYAD SA/ADR from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded CELYAD SA/ADR from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Wednesday, November 13th. Five analysts have rated the stock with a buy rating, CELYAD SA/ADR has an average rating of “Buy” and a consensus target price of $26.00.
Shares of CYAD stock opened at $12.56 on Friday. The stock has a market cap of $112.45 million, a P/E ratio of -3.16 and a beta of 1.14. CELYAD SA/ADR has a 1 year low of $8.10 and a 1 year high of $28.35. The stock has a 50 day simple moving average of $9.46 and a 200 day simple moving average of $13.15.
A hedge fund recently raised its stake in CELYAD SA/ADR stock. Morgan Stanley raised its position in shares of CELYAD SA/ADR (NASDAQ:CYAD) by 24.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,473 shares of the company’s stock after acquiring an additional 2,488 shares during the quarter. Morgan Stanley owned about 0.13% of CELYAD SA/ADR worth $143,000 as of its most recent SEC filing. 9.91% of the stock is currently owned by hedge funds and other institutional investors.
CELYAD SA/ADR Company Profile
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.